The FDA’s investigation into Zolgensma follows Novartis’ disclosure that cancer risk may be higher than previously appreciated in the gene therapy’s real-world and follow-up data. The move illustrates how regulator assessment can accelerate once new post-marketing safety information emerges, particularly for therapies with potential latency in malignancy signals. Biotech stakeholders will watch how the FDA frames the risk and what follow-up evidence the agency requires for risk mitigation and ongoing study designs.